1-3 of 3
Andrew G. Bosanquet, PhD
Close
Sort by
Journal Articles

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

Teresa A Bennett, Ph.D., Sandra Sapia, MD, Daniel Primo, PhD, Lilia Suarez, PhD, Santiago Lago, PhD, Maria Matoses, PhD, Ana Espinosa, PhD, Consuelo Tudela, PhD, Elena Arroyo, PhD, Julian Gorrochategui, PhD, William C Jackson, PhD, Alex Okun, PhD, Horacio Hector Lopez, PhD, Isolde Gornemann, MD, Soledad Gallego Melcon, MD, Cristina Diaz de Heredia, MD, Jose Luis Dapena, MD, Josep M Roma, MD, Regina Garcia Delgado, MD, Mari Paz Queipodellano, MD, Alicia Bailen, MD, Manuel Barrios, Eva Diez, PhD, Santiago Del Castillo, MD, PhD, Ana Isabel Heiniger, Jose Sanchez de Toledo, Manuel Ramirez, Sr., MD, PhD, Macarena Ortiz, MD, Marcos Gonzáalez, Jesús F. San-Miguel, MD, PhD, Enrique M Ocio, Andrew G. Bosanquet, PhD, MRCPath, Alberto Orfao, MD, PhD, Joan Ballesteros, PhD
Journal: Blood
Blood (2009) 114 (22): 2655.
https://doi.org/10.1182/blood.V114.22.2655.2655
Published: 2009
Journal Articles

Individualized Tumor Response (ITR) Profiling for Drug Selection in Tailored Therapy: Meta-Analysis of 1929 Cases of Leukemia and Lymphoma.

Andrew G. Bosanquet, PhD, MRCPath, Gertjan J. Kaspers, MD, PhD, Rolf Larsson, MD, Robert A. Nagourney, MD, PhD, Peter Nygren, MD, PhD, Rob Pieters, MD, PhD, Peter Staib, MD, Ulf Tidefelt, MD, PhD, C. Michel Zwaan, MD, PhD, Larry M. Weisenthal, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 3471.
https://doi.org/10.1182/blood.V110.11.3471.3471
Published: 2007
Journal Articles

Drug Sensitivity by TRAC (DiSC) Assay as a Prognostic Factor for Patient Response in Untreated CLL: Results from the UK LRF CLL4 Trial.

Andrew G. Bosanquet, PhD, Steve L. Raper, BSc, Justin Durant, Sheila M. Scadding, David Graham Oscier, MD, Sue M. Richards, PhD, Daniel Catovsky, MD PhD, on Behalf of the NCRI CLL Working Group
Journal: Blood
Blood (2006) 108 (11): 303.
https://doi.org/10.1182/blood.V108.11.303.303
Published: 2006